{"id":"halcinonide","rwe":[{"pmid":"41263638","year":"2026","title":"Cu-Fe bimetallic nanozyme@halloysite-sodium alginate composite hydrogels for the treatment of atopic dermatitis.","finding":"","journal":"Biomaterials science","studyType":"Clinical Study"},{"pmid":"40792069","year":"2025","title":"Identification of key modules and hub genes for sepsis-induced myopathy using weighted gene co-expression network analysis.","finding":"","journal":"Frontiers in genetics","studyType":"Clinical Study"},{"pmid":"39710062","year":"2025","title":"Halcinonide activates smoothened to ameliorate ischemic stroke injury.","finding":"","journal":"Life sciences","studyType":"Clinical Study"},{"pmid":"39363827","year":"2024","title":"Single-Atom Catalysts with Isolated Cu(1)-N(4) Sites for Atopic Dermatitis Cascade Catalytic Therapy via Activating PPAR Signaling.","finding":"","journal":"Small (Weinheim an der Bergstrasse, Germany)","studyType":"Clinical Study"},{"pmid":"39083867","year":"2024","title":"Exposure to synthetic steroid hormones and precocious puberty in girls: A case-control study.","finding":"","journal":"Ecotoxicology and environmental safety","studyType":"Clinical Study"}],"_fda":{"id":"42dc2391-6bbc-bd57-e063-6294a90a7ef7","set_id":"42dc0904-1800-5f3b-e063-6294a90a2ad2","openfda":{"nui":["N0000175576","N0000175450"],"unii":["SI86V6QNEG"],"route":["TOPICAL"],"rxcui":["206550","310669"],"spl_id":["42dc2391-6bbc-bd57-e063-6294a90a7ef7"],"brand_name":["HALOG"],"spl_set_id":["42dc0904-1800-5f3b-e063-6294a90a2ad2"],"package_ndc":["64950-127-12"],"product_ndc":["64950-127"],"generic_name":["HALCINONIDE TOPICAL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["HALCINONIDE"],"pharm_class_epc":["Corticosteroid [EPC]"],"pharm_class_moa":["Corticosteroid Hormone Receptor Agonists [MoA]"],"manufacturer_name":["Genus Lifesciences Inc."],"application_number":["NDA017823"],"is_original_packager":[true]},"version":"1","pregnancy":["Pregnancy Teratogenic Effects Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time."],"overdosage":["OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS: General )."],"description":["DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti- inflammatory and antipruritic agents. The steroids in this class include halcinonide. Halcinonide is designated chemically as 21-Chloro-9-fluoro-11β, 16α, 17-trihydroxypregn-4-ene-3, 20-dione cyclic 16, 17-acetal with acetone. Structural formula: C 24 H 32 ClFO 5 , MW 454.96, CAS-3093-35-4 Each mL of 0.1% HALOG SOLUTION (Halcinonide Topical Solution, USP) contains 1 mg halcinonide, edetate disodium, polyethylene glycol 300, and purified water with butylated hydroxytoluene as an antioxidant. Structure"],"precautions":["PRECAUTIONS General Systemic absorption of topical corticosteroids has produced reversible hypothalamic- pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of any potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique. Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Occasionally, a patient may develop a sensitivity reaction to a particular occlusive dressing material or adhesive and a substitute material may be necessary. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS: Pediatric Use ). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. This preparation is not for ophthalmic use. Information for the Patient Patients using topical corticosteroids should receive the following information and instructions: 1) This medication is to be used as directed by the physician. It is for dermatologic use only. Avoid contact with the eyes. 2) Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3) The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. 4) Patients should report any signs of local adverse reactions especially under occlusive dressing. 5) Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings. Laboratory Tests A urinary free cortisol test and ACTH stimulation test may be helpful in evaluating HPA axis suppression. Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone showed negative results. Pregnancy Teratogenic Effects Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman. Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid- induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. HPA axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children. Geriatric Use Clinical studies of 0.1% HALOG SOLUTION (Halcinonide Topical Solution, USP) did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range."],"how_supplied":["HOW SUPPLIED HALOG® SOLUTION (Halcinonide Topical Solution, USP) 0.1% is supplied in plastic squeeze bottles containing 120 mL (NDC 64950-127-12) of solution. Storage Store at room temperature; avoid freezing and temperatures above 104° F. To report SUSPECTED ADVERSE REACTIONS, contact Allucent at 1-866-511-6754 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Distributed by: Genus Lifesciences Inc. Allentown, PA 18102 Revised: May 2025 5261181 50"],"geriatric_use":["Geriatric Use Clinical studies of 0.1% HALOG SOLUTION (Halcinonide Topical Solution, USP) did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range."],"pediatric_use":["Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid- induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. HPA axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children."],"effective_time":"20251105","nursing_mothers":["Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman."],"laboratory_tests":["Laboratory Tests A urinary free cortisol test and ACTH stimulation test may be helpful in evaluating HPA axis suppression."],"adverse_reactions":["ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria."],"contraindications":["CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations."],"general_precautions":["General Systemic absorption of topical corticosteroids has produced reversible hypothalamic- pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of any potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or elevation of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or use a sequential approach when utilizing the occlusive technique. Recovery of HPA axis function and thermal homeostasis are generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Occasionally, a patient may develop a sensitivity reaction to a particular occlusive dressing material or adhesive and a substitute material may be necessary. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS: Pediatric Use ). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. This preparation is not for ophthalmic use."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION ). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile."],"indications_and_usage":["INDICATIONS AND USAGE HALOG SOLUTION (Halcinonide Topical Solution, USP) 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."],"information_for_patients":["Information for the Patient Patients using topical corticosteroids should receive the following information and instructions: 1) This medication is to be used as directed by the physician. It is for dermatologic use only. Avoid contact with the eyes. 2) Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3) The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. 4) Patients should report any signs of local adverse reactions especially under occlusive dressing. 5) Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings."],"spl_unclassified_section":["Rx Only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Apply HALOG SOLUTION (Halcinonide Topical Solution, USP) 0.1% to the affected area two to three times daily. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Apply the solution to the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply Halcinonide Topical Solution, USP 0.1% under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional solution should be applied, without occlusion, during the day. Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted."],"spl_product_data_elements":["HALOG Halcinonide Topical BUTYLATED HYDROXYTOLUENE EDETATE DISODIUM POLYETHYLENE GLYCOL 300 WATER HALCINONIDE HALCINONIDE"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 64950-127-12 HALOG ® SOLUTION (Halcinonide Topical Solution, USP 0.1%) FOR DERMATOLOGIC USE Not For Ophthalmic Use Net Wt. 120 ml Rx only carton label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone showed negative results."]},"tags":[{"label":"Corticosteroid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glucocorticoid receptor","category":"target"},{"label":"NR3C1","category":"gene"},{"label":"D07AD02","category":"atc"},{"label":"Topical","category":"route"},{"label":"Cream","category":"form"},{"label":"Ointment","category":"form"},{"label":"Solution","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Atopic dermatitis","category":"indication"},{"label":"Contact dermatitis","category":"indication"},{"label":"Discoid lupus erythematosus","category":"indication"},{"label":"Eruption of skin","category":"indication"},{"label":"Granuloma annulare","category":"indication"},{"label":"Lichen simplex chronicus","category":"indication"},{"label":"Sun Pharm Inds Inc","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"skin atrophy","drugRate":"reported","severity":"unknown"},{"effect":"miliaria","drugRate":"reported","severity":"unknown"},{"effect":"striae","drugRate":"reported","severity":"unknown"},{"effect":"maceration of the skin","drugRate":"reported","severity":"unknown"},{"effect":"allergic contact dermatitis","drugRate":"reported","severity":"unknown"},{"effect":"perioral dermatitis","drugRate":"reported","severity":"unknown"},{"effect":"hypopigmentation","drugRate":"reported","severity":"unknown"},{"effect":"acneiform eruptions","drugRate":"reported","severity":"unknown"},{"effect":"hypertrichosis","drugRate":"reported","severity":"unknown"},{"effect":"folliculitis","drugRate":"reported","severity":"unknown"},{"effect":"dryness","drugRate":"reported","severity":"unknown"},{"effect":"irritation","drugRate":"reported","severity":"unknown"},{"effect":"itching","drugRate":"reported","severity":"unknown"},{"effect":"burning","drugRate":"reported","severity":"unknown"},{"effect":"secondary infection","drugRate":"reported","severity":"unknown"}],"contraindications":["Atrophoderma","Bilateral cataracts","Diabetes mellitus type 1","Diabetes mellitus type 2","Glaucoma","Peripheral vascular disease","Tuberculosis of skin"],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.","Geriatric use":"Of approximately 3000 patients included in clinical studies of 0.1% halcinonide cream, 14% were 60 years or older, while 4% were 70 years or older. No overall differences in safety were observed between these patients and younger patients. Efficacy data have not been evaluated for differences between elderly and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some elderly individuals cannot be ruled out.","Paediatric use":"Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushings syndrome than mature patients because of larger skin surface area to body weight ratio.HPA axis suppression, Cushings syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and other signs and symptoms of adrenal insufficiency."}},"trials":[],"aliases":[],"company":"Sun Pharma","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HALCINONIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:17:39.381220+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:17:44.367495+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:17:38.498308+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HALCINONIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:17:44.700076+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:17:34.259173+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:17:34.259200+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:17:34.259206+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3039407/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:17:45.398623+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA017823","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:17:34.259209+00:00"}},"allNames":"halog","offLabel":[],"synonyms":["halcinonide","alcinonide","halciderm","halcimat","halog"],"timeline":[{"date":"1974-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from RANBAXY to Sun Pharm Inds Inc"},{"date":"1974-11-27","type":"positive","source":"DrugCentral","milestone":"FDA approval (Ranbaxy)"},{"date":"2019-08-12","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Halog (Halcinonide) is a corticosteroid medication originally developed by Ranbaxy and currently owned by Sun Pharma Industries Inc. It targets the glucocorticoid receptor to treat various skin conditions, including atopic dermatitis, contact dermatitis, and plaque psoriasis. Halog is a small molecule corticosteroid that has been FDA-approved since 1974 and is now available as a generic medication. It is used to reduce inflammation and itching in the skin. As an off-patent medication, Halog is widely available from multiple generic manufacturers.","approvals":[{"date":"1974-11-27","orphan":false,"company":"RANBAXY","regulator":"FDA"}],"brandName":"Halog","ecosystem":[{"indication":"Atopic dermatitis","otherDrugs":[{"name":"abrocitinib","slug":"abrocitinib","company":"PFIZER Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"}],"globalPrevalence":204050000},{"indication":"Contact dermatitis","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"}],"globalPrevalence":324000000},{"indication":"Discoid lupus erythematosus","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"}],"globalPrevalence":2400000},{"indication":"Eruption of skin","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"}],"globalPrevalence":null},{"indication":"Granuloma annulare","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"benzoyl peroxide","slug":"benzoyl-peroxide","company":"Valeant Intl"}],"globalPrevalence":null},{"indication":"Lichen simplex chronicus","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"}],"globalPrevalence":null},{"indication":"Plaque psoriasis","otherDrugs":[{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"},{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"alefacept","slug":"alefacept","company":"Astellas"},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"}],"globalPrevalence":125000000},{"indication":"Primary cutaneous T-cell lymphoma","otherDrugs":[{"name":"alclometasone dipropionate","slug":"alclometasone-dipropionate","company":""},{"name":"amcinonide","slug":"amcinonide","company":"Astellas"},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone benzoate","slug":"betamethasone-benzoate","company":"Parke Davis"}],"globalPrevalence":null}],"mechanism":{"target":"Glucocorticoid receptor","novelty":"Follow-on","targets":[{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"}],"moaClass":"Corticosteroid Hormone Receptor Agonists","modality":"Small Molecule","drugClass":"Corticosteroid [EPC]","explanation":"","oneSentence":"","technicalDetail":"Halog (Halcinonide) is a potent topical corticosteroid that exerts its effects by binding to the glucocorticoid receptor (GR), a transcription factor that regulates the expression of anti-inflammatory genes. This binding event triggers a cascade of downstream effects, including the inhibition of pro-inflammatory cytokines and the induction of anti-inflammatory cytokines, ultimately leading to reduced inflammation and itching in the skin."},"commercial":{"launchDate":"1974","_launchSource":"DrugCentral (FDA 1974-11-27, RANBAXY)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4507","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=HALCINONIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HALCINONIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T11:51:03.112159","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:17:48.134938+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"clobetasol propionate","drugSlug":"clobetasol-propionate","fdaApproval":"1985-12-27","patentExpiry":"Nov 5, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"halcinonide","indications":{"approved":[{"name":"Atopic dermatitis","source":"DrugCentral","snomedId":24079001,"regulator":"FDA","eligibility":"corticosteroid-responsive","usPrevalence":null,"globalPrevalence":204050000,"prevalenceMethod":"curated","prevalenceSource":"Br J Dermatol, 2023 (PMID:37705227)"},{"name":"Contact dermatitis","source":"DrugCentral","snomedId":40275004,"regulator":"FDA","eligibility":"corticosteroid-responsive","usPrevalence":null,"globalPrevalence":324000000,"prevalenceMethod":"curated","prevalenceSource":"Contact Dermatitis, 2025 (PMID:40107276)"},{"name":"Discoid lupus erythematosus","source":"DrugCentral","snomedId":200938002,"regulator":"FDA","eligibility":"corticosteroid-responsive","usPrevalence":null,"globalPrevalence":2400000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (ORPHANET)"},{"name":"Eruption of skin","source":"DrugCentral","snomedId":271807003,"regulator":"FDA","eligibility":"corticosteroid-responsive"},{"name":"Granuloma annulare","source":"DrugCentral","snomedId":65508009,"regulator":"FDA","eligibility":"corticosteroid-responsive"},{"name":"Lichen simplex chronicus","source":"DrugCentral","snomedId":53891004,"regulator":"FDA","eligibility":"corticosteroid-responsive"},{"name":"Plaque psoriasis","source":"DrugCentral","snomedId":200965009,"regulator":"FDA","eligibility":"corticosteroid-responsive","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Primary cutaneous T-cell lymphoma","source":"DrugCentral","snomedId":400122007,"regulator":"FDA","eligibility":"corticosteroid-responsive"},{"name":"Pruritus ani","source":"DrugCentral","snomedId":90446007,"regulator":"FDA","eligibility":"corticosteroid-responsive"},{"name":"Pruritus of genital organs","source":"DrugCentral","snomedId":267802000,"regulator":"FDA","eligibility":"corticosteroid-responsive"},{"name":"Scalp psoriasis","source":"DrugCentral","snomedId":238608008,"regulator":"FDA","usPrevalence":7500000,"globalPrevalence":125000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Seborrheic dermatitis","source":"DrugCentral","snomedId":50563003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Sun Pharm Inds Inc","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"clobetasol-propionate","brandName":"clobetasol propionate","genericName":"clobetasol propionate","approvalYear":"1985","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04347473","phase":"PHASE4","title":"ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2020-04-06","conditions":["Psoriasis"],"enrollment":25,"completionDate":"2021-03-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Cream, Ointment, Solution","formulations":[{"form":"CREAM","route":"TOPICAL","productName":"Halcinonide"},{"form":"CREAM","route":"TOPICAL","productName":"Halog"},{"form":"CREAM","route":"TOPICAL","productName":"HALCINONIDE"},{"form":"OINTMENT","route":"TOPICAL","productName":"HALOG"},{"form":"SOLUTION","route":"TOPICAL","productName":"HALOG"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000145986","MMSL":"321821","NDDF":"002200","UNII":"SI86V6QNEG","VUID":"4017606","CHEBI":"CHEBI:31663","VANDF":"4017606","INN_ID":"3392","RXNORM":"227517","UMLSCUI":"C0018513","chemblId":"CHEMBL3039407","ChEMBL_ID":"CHEMBL1200845","KEGG_DRUG":"D01308","DRUGBANK_ID":"DB06786","PUBCHEM_CID":"443943","SNOMEDCT_US":"29058003","MESH_DESCRIPTOR_UI":"D006206"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1974-","companyName":"Ranbaxy","relationship":"Original Developer"},{"period":"present","companyName":"Sun Pharm Inds Inc","relationship":"Current Owner"}],"publicationCount":88,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"D07AD02","allCodes":["D07AD02"]},"biosimilarFilings":[],"originalDeveloper":"Ranbaxy","recentPublications":[{"date":"2026 Jan 6","pmid":"41263638","title":"Cu-Fe bimetallic nanozyme@halloysite-sodium alginate composite hydrogels for the treatment of atopic dermatitis.","journal":"Biomaterials science"},{"date":"2025","pmid":"40792069","title":"Identification of key modules and hub genes for sepsis-induced myopathy using weighted gene co-expression network analysis.","journal":"Frontiers in genetics"},{"date":"2025 Jan 15","pmid":"39710062","title":"Halcinonide activates smoothened to ameliorate ischemic stroke injury.","journal":"Life sciences"},{"date":"2024 Dec","pmid":"39363827","title":"Single-Atom Catalysts with Isolated Cu(1)-N(4) Sites for Atopic Dermatitis Cascade Catalytic Therapy via Activating PPAR Signaling.","journal":"Small (Weinheim an der Bergstrasse, Germany)"},{"date":"2024 Sep 15","pmid":"39083867","title":"Exposure to synthetic steroid hormones and precocious puberty in girls: A case-control study.","journal":"Ecotoxicology and environmental safety"}],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Chartwell Rx","Encube","Mylan"],"status":"approved","companyName":"Sun Pharm Inds Inc","companyId":"sun-pharma","modality":"Small molecule","firstApprovalDate":"1974","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1974-11-27T00:00:00.000Z","mah":"RANBAXY","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1978-01-09T00:00:00.000Z","mah":"SUN PHARM INDS INC","brand_name_local":null,"application_number":"NDA017823"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1978-01-09T00:00:00.000Z","mah":"SUN PHARM INDS INC","brand_name_local":null,"application_number":"NDA017556"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-08-12T00:00:00.000Z","mah":"MYLAN","brand_name_local":null,"application_number":"ANDA211027"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-05-29T00:00:00.000Z","mah":"ENCUBE","brand_name_local":null,"application_number":"ANDA217671"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:17:48.134938+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}